These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35488944)

  • 21. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
    Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
    Kolkhof P; Bärfacker L
    J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
    Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.
    Yoshihara K; Fukae M; Kastrissios H; Wada R; Shimizu T
    Drug Metab Pharmacokinet; 2024 Apr; 55():100535. PubMed ID: 38245949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
    Lo KB; Rangaswami J; Vaduganathan M
    Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
    Sato A; Nishimoto M
    Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
    Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptor blockers and chronic kidney disease.
    Jain G; Campbell RC; Warnock DG
    Clin J Am Soc Nephrol; 2009 Oct; 4(10):1685-91. PubMed ID: 19729430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
    Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
    Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
    Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
    Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist's treatment: A review].
    Bobkova IN
    Ter Arkh; 2023 Nov; 95(9):796-801. PubMed ID: 38158924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
    Haller H; Bertram A; Stahl K; Menne J
    Curr Hypertens Rep; 2016 Apr; 18(5):41. PubMed ID: 27115525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
    Bonnard B; Pieronne-Deperrois M; Djerada Z; Elmoghrabi S; Kolkhof P; Ouvrard-Pascaud A; Mulder P; Jaisser F; Messaoudi S
    J Mol Cell Cardiol; 2018 Aug; 121():124-133. PubMed ID: 29981797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.
    Ishikawa T; Morimoto S; Ichihara A
    Hypertens Res; 2022 Mar; 45(3):496-506. PubMed ID: 34961793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.
    Liu W; Yu S
    Kidney Dis (Basel); 2023 Jan; 9(1):12-25. PubMed ID: 36756081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.